PRSS56 and scoliosis: Combined treatment with selumetinib and RMC-4550 effectively prevented scoliosis in Prss56-Nf1fl/- mice while 33.3% (5/15) and 50% (7/14) of vehicle-treated mice developed scoliosis by 12 and 16 months, respectively (Figs. 5b-d, S7a).